Equity research analysts covering Orchid Pharma maintain a balanced mix of ratings reflecting its domestic formulation growth and regulatory export pipeline, with institutions like JM Financial issuing buy recommendations with price targets near 1,150 rupees, while firms like ICICI Securities maintain neutral stances around 1,080 rupees, yielding a consensus target hovering near 1,115 rupees.